A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
As mesothelin is overexpressed in various types of cancer, it is an attractive target for therapeutic antibodies. T-cell bispecific antibodies bind to target cells and engage T cells via binding to CD3, resulting in target cell killing by T-cell activation. However, the affinity of the CD3-binding a...
Main Authors: | Aerin Yoon, Shinai Lee, Sua Lee, Sojung Lim, Yong-Yea Park, Eunjung Song, Dong-Sik Kim, Kisu Kim, Yangmi Lim |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/10/3/399 |
Similar Items
-
A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
by: Joanie Del Bano, et al.
Published: (2019-07-01) -
Bispecific antibodies with Fab-arms featuring exchanged antigen-binding constant domains
by: Filippo Benedetti, et al.
Published: (2021-07-01) -
Immunoglobulin Fc heterodimer platform technology: From design to applications in therapeutic antibodies and proteins
by: Ji-Hee Ha, et al.
Published: (2016-10-01) -
Engineering IgG-Like Bispecific Antibodies—An Overview
by: Simon Krah, et al.
Published: (2018-08-01) -
Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
by: Mingpeng Fu, et al.
Published: (2019-06-01)